ABBOTT LABORATORIES(ABT)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #491 of 2,879 stocksTOP 25%
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
ABT Stock Analysis & AI Quality Score
AI stock analysis and institutional research for ABBOTT LABORATORIES (ABT), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ABT at 67.0/100 on a 32-signal composite quality model, placing it at rank #491 of 2,879 stocks — the top 25% of the AI-ranked universe. ABT scores in the top quartile across revenue scale (96.8), balance sheet strength (77.6). Areas of concern include institutional flow (17.0), which score below median versus the broader universe. Shareholder dilution risk is elevated at 47.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), ABBOTT LABORATORIES reports quarterly revenue of $11.2B, net income of $1.1B, an operating margin of 12.0%. Top institutional holders of ABT by reported 13-F value include BlackRock,, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. ABT trades on the NYSE exchange and files with the SEC under CIK 1800. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ABT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ABBOTT LABORATORIES directly from SEC EDGAR. ABBOTT LABORATORIES's 13F Pro composite quality score has ranged between 44 and 79 since 2021, currently 67.0 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.
What's Driving ABT's Business? Latest 10-Q Breakdown
✓ 22/22 datapoints verifiedAI-extracted from ABBOTT LABORATORIES's 10-Q filed 2026-04-29 — Q1 2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Abbott reported Q1 2026 net sales of $11.2B (+7.8% YoY), with Medical Devices driving growth; completed $20.6B acquisition of Exact Sciences on March 23, 2026.
Biggest Revenue Drivers
Total revenue: $11.2B+7.8% YoY
Double-digit growth in Rhythm Management, Electrophysiology, and Heart Failure; Diabetes Care CGM systems grew 7.6% excluding FX impact.
Core Laboratory growth of 3.3% ex-FX offset by Rapid and Molecular decline of 9.6% ex-FX; includes Exact Sciences Cancer Diagnostics $96M from March 23.
Lower sales volumes across pediatric and adult nutritional portfolios in U.S. and internationally.
Key Emerging Markets sales grew 9.4% excluding FX impact, led by double-digit growth in Latin America and Asia Pacific.
Largest Expense Items
Acquisition and integration of Exact Sciences, including $321M stock-based compensation from equity award cash out; increased selling and marketing spending; unfavorable FX impact.
Unfavorable impact of higher costs and foreign exchange partially offset by margin improvement initiatives.
Higher spending on development programs across multiple businesses.
Intangible asset amortization expense; estimated annual amortization approximately $2.6B in 2026.
Margins: Gross profit margin decreased to 52.4% in Q1 2026 from 52.8% in Q1 2025, reflecting higher costs and unfavorable foreign exchange, partially offset by margin improvement initiatives. Operating margin pressured by increased SG&A expenses from Exact Sciences acquisition integration.
Watch Items from the Filing
- Abbott completed $20.6B acquisition of Exact Sciences on March 23, 2026, funded by $20B debt issuance; assumed $2.8B Exact Sciences debt and repaid $1.4B in March, remaining expected repaid in 2026.
- IRS disputes: Abbott contests $417M (2019), $192M (2017-2018), and $443M (2020) income tax assessments related to intercompany income allocation; $413M Malaysian tax assessment upheld in October 2025; appeals ongoing.
- Abbott faces multiple NEC (necrotizing enterocolitis) lawsuits alleging preterm infant formula caused intestinal disease; prevailed on summary judgment in three federal MDL bellwether cases; one state court case resulted in $495M plaintiff verdict; outcomes vary across cases.
- Nutritional Products sales declined 6.0% YoY due to lower volumes; Rapid and Molecular Diagnostics sales declined 9.6% ex-FX due to weaker respiratory virus season, indicating segment headwinds.
- Remaining performance obligations of $6.9B across segments; Diagnostic Products $6.2B (multi-period extended service arrangements and minimum purchase obligations); approximately 52% expected to be recognized over next 24 months.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Revenue
Q1 2026
$11.2B
Net Income
Q1 2026
$1.1B
Free Cash Flow
Q1 2026
$916.0M
Operating Margin
Q1 2026
12.0%
D/E Ratio
Q1 2026
0.65
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+5.7% YoYNet Income
-51.3% YoYOperating Income
+18.0% YoYEPS (Diluted)
-51.3% YoYTotal Assets
+6.5% YoYTotal Debt
+2.2% YoYOp. Cash Flow
+11.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $44.33B +5.7% | $41.95B +4.6% | $40.11B -8.1% | $43.65B +1.3% | $43.08B +24.5% | $34.61B |
| Net Income | $6.52B -51.3% | $13.40B +134.2% | $5.72B -17.5% | $6.93B -2.0% | $7.07B +57.3% | $4.50B |
| Operating Income | $8.05B +18.0% | $6.83B +5.4% | $6.48B -22.5% | $8.36B -0.7% | $8.43B +57.3% | $5.36B |
| EPS (Diluted) | $3.72 -51.3% | $7.64 +134.4% | $3.26 -16.6% | $3.91 -0.8% | $3.94 +57.6% | $2.50 |
| Total Assets | $86.71B +6.5% | $81.41B +11.2% | $73.21B -1.6% | $74.44B -1.0% | $75.20B +3.6% | $72.55B |
| Total Debt | $15.96B +2.2% | $15.63B -0.9% | $15.76B -17.2% | $19.02B +1.2% | $18.80B +0.3% | $18.75B |
| Operating Cash Flow | $9.57B +11.8% | $8.56B +17.9% | $7.26B -24.2% | $9.58B -9.0% | $10.53B +33.3% | $7.90B |
AI Insight: ABT Financial Trends
Abbott's Q1 2026 debt nearly tripled to $34.0B while operating income fell 37% YoY, signaling a major capital event that overwhelmed operational momentum.
• Revenue grew 7.8% from Q1 2025 ($10,358M) to Q1 2026 ($11,164M), marking consistent mid-single-digit expansion.
• Operating margin compressed sharply: Q4 2025 margin was 19.6%, but Q1 2026 dropped to 12.0%, a 160 bp decline.
• Operating cash flow halved from Q4 2025 ($3,315M) to Q1 2026 ($1,315M), the lowest in eight quarters.
⚠ Total debt jumped from $15,962M (Q4 2025) to $34,047M (Q1 2026)—a $18.1B increase. Debt-to-equity ratio rose to 65.3% from 30.6%.
⚠ Net income crashed 39% YoY (Q1 2025: $1,325M vs. Q1 2026: $1,077M) amid margin and cash-flow pressure.
AI Insight: ABT Ratio Trends
Abbott's Q1 2026 profitability collapsed across all metrics, with operating margin plunging to 12.0% from 19.6% in Q4 2025 and ROIC falling to 6.2% from 13.2%.
• Operating margin declined 7.6pp Q4 2025 to Q1 2026 (19.6% → 12.0%), worst quarter in dataset. NPM fell to 9.7% from 15.5%.
• ROIC compressed 7.0pp to 6.2% in Q1 2026, reversing three consecutive quarters of 12.8%–13.2% performance.
• Leverage spiked: D/E ratio jumped to 0.65 in Q1 2026 from 0.31 in Q4 2025, erasing prior deleveraging progress.
⚠ Q1 2026 earnings quality concern: massive Q4 2024 NPM spike (84.1%) suggests one-off gains; normalization persists into Q1 2026.
⚠ Monitor if Q1 2026 decline is seasonal/cyclical or signals operational headwinds. TTM metrics also deteriorated materially.
Get alerted when ABT's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for ABBOTT LABORATORIES including:
Top Institutional Holders of ABT
BlackRock, Inc.
$15.0B145,687,458 shVANGUARD CAPITAL MANAGEMENT LLC
$11.6B112,949,933 shSTATE STREET CORP
$8.2B79,575,468 shCapital Research Global Investors
$5.1B49,775,362 shVANGUARD PORTFOLIO MANAGEMENT LLC
$4.9B47,944,891 shCHARLES SCHWAB INVESTMENT MANAGEMENT INC
$4.7B45,500,055 shGEODE CAPITAL MANAGEMENT, LLC
$4.0B39,148,795 shCapital International Investors
$3.8B37,498,227 shMORGAN STANLEY
$3.1B30,101,596 shWELLINGTON MANAGEMENT GROUP LLP
$2.8B27,070,518 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $15.0B | 145,687,458 |
| VANGUARD CAPITAL MANAGEMENT LLC | $11.6B | 112,949,933 |
| STATE STREET CORP | $8.2B | 79,575,468 |
| Capital Research Global Investors | $5.1B | 49,775,362 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $4.9B | 47,944,891 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $4.7B | 45,500,055 |
| GEODE CAPITAL MANAGEMENT, LLC | $4.0B | 39,148,795 |
| Capital International Investors | $3.8B | 37,498,227 |
| MORGAN STANLEY | $3.1B | 30,101,596 |
| WELLINGTON MANAGEMENT GROUP LLP | $2.8B | 27,070,518 |
More Healthcare Companies
View all Healthcare →Put ABT on your watchlist
Track score changes the day ABBOTT LABORATORIES files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ABT a good stock to buy?
13F Pro's AI-powered analysis of ABBOTT LABORATORIES (ABT) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ABT are available on the ABT stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ABT?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ABT. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of ABBOTT LABORATORIES's investment landscape.